ArticleJournal of biological engineering2026
Optimization of serum-free medium supplemented with microalgal extract using response surface methodology for human fibroblast culture.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAnimal cell culture has become an essential tool in biomedical research and industrial vaccine and biopharmaceutical development. Fetal bovine serum (FBS) is widely used as a culture supplement because of its rich composition of nutrients and growth factors. However, concerns over pathogen contamination and immunogenicity have prompted regulatory agencies to discourage its clinical application and motivated the development of serum-free media alternatives.
resultsIn this study, a serum-free medium was developed for human lung fibroblasts (MRC-5) and optimized using response surface methodology in terms of the growth factor contents: EGF (9.3 ng/mL), IGF-1 (4.0 ng/mL), IGF-2 (4.3 ng/mL), ITS (4.5 µg/mL), and PDGF-CC (6.9 ng/mL). The optimized growth factor mixture (OGM) (G2/M, 32.0%) and addition of 200 µg/mL of Haematococcus pluvialis extracts (HE200) (OGM + HE200, G2/M, 35.3%) significantly enhanced cell proliferation by promoting cell cycle progression, particularly the G2/M phase compare with DMEM (G2/M, 15.0%). Moreover, Ki-67, a nuclear proliferation marker, showed increased expression in OGM-treated cells (mRNA, 2.7 fold) compared with those cultured in DMEM as evaluated by immunocytochemistry and qPCR. The addition of HE200 (mRNA, 4.0 fold) exerted synergistic effects with OGM, further promoting cell proliferation and the expression of cell cycle–related genes.
conclusionsThe study demonstrated the potential of combining an OGM and HE to support cell growth under serum-free conditions, providing a functional alternative to FBS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.